About: http://data.cimple.eu/news-article/2ab29f9365b27e943d8be0b46bd37d23fb567f403a4fd9acb4a5ee59     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • Chinese pharmaceutical firm Sinovac Biotech has secured half a billion dollars in extra funding to produce its Covid-19 vaccine, it said Monday, as the country races to roll out a jab for general use. Beijing has largely brought the virus under control, with only 281 active cases still receiving treatment, according to official figures. But it has promised to make its vaccines available as a "global public good" as it seeks to counter global criticism for its early handling of the pandemic. Sino Biopharmaceutical Limited, a Hong Kong-listed medical research firm, said on Monday that it will invest $515 million for the development and production of CoronaVac, one of Sinovac's most advanced vaccine candidates. Sinovac -- one of China's leading vaccine producers -- said the funding will be used for the "further development, capacity expansion and manufacturing" of CoronaVac. It added it hoped to be able to manufacture 600 million doses by the end of the year. Sino Biopharmaceutical will receive a 15 percent share in a Sinovac subsidiary, Sinovac Life Sciences, under the agreement. Although regulators have yet to approve China's vaccines for mass distribution, the country has approved some advanced candidates for emergency use. Since July a range of people from state employees to international students have been given jabs. CoronaVac is being tested in multiple countries including Brazil, where final-stage clinical trials for the jab have restarted after hitting a setback in November when a volunteer experienced an "adverse incident." The vaccine "has reached critical milestones in clinical trials in Asia and Latin America," Sinovac CEO Yin Weidong said in the statement. The company earlier said almost all its employees and their families have voluntarily taken the vaccine. Sinopharm, another Chinese vaccine maker, said in November that nearly a million people have already taken its experimental Covid-19 vaccine. Last week Britain became the first Western country to approve a vaccine for general use, piling pressure on other countries to follow suit swiftly. tjx/rox/reb/rma
schema:headline
  • Chinese Covid-19 vaccine maker gets $500 million funding boost
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software